A New Milestone in Diabetes Care The FDA has officially granted approval for Garzuly (insulin aspart), a significant development for patients managing diabetes. As a biosimilar to NovoLog, Garzuly offers an alternative treatment option for individuals requiring insulin aspart to improve glycemic control. What You Need to Know About Garzuly Biosimilars are designed to be…